Introduction
Angiogenesis, the growth of new blood vessels, is of key importance in a broad array of physiological and pathological conditions ranging from inflammation, and cancer to age-related macular degeneration. Regulation of angiogenesis is often viewed as a balance between pro-angiogenic and anti-angiogenic factors, and when the balance shifts in favor of pro-angiogenic factors, an angiogenic switch turns on the normally inactive endothelial cells to grow new blood vessels. Activation of VEGFR-2 is considered a pivotal signaling event that determines many aspects of endothelial cells function, including differentiation, proliferation and migration (reviewed in Olsson et al., 2006 , Rahimi, 2006 . Although these outcomes are initially determined by the presence of the VEGF ligands, in the recent years, it has become evident that protein ubiquitination involving c-Cbl ubiquitin E3 ligase also significantly amend the angiogenic signaling events, particularly by targeting PLCg1 (phospholipase Cg1), the major substrate of VEGFR-2 in endothelial cells (Singh et al., 2005 (Singh et al., , 2007 .
The Cbl family ubiquitin E3 ligase proteins consist of three closely related proteins, including c-Cbl, Cbl-b and Cbl-3. All of c-Cbl family gene products contain a highly conserved tyrosine kinase binding (TKB) domain and a RING-finger domain in their N-terminal region. The C-terminus of Cbl family proteins interacts with various SH2 and SH3 domain-containing proteins (Thien and Langdon, 2005) . The c-Cbl protein primarily functions as an E3 ubiquitin ligase where its RINGfinger domain recruits ubiquitin-conjugating (E2) enzyme (Swaminathan and Tsygankov, 2006) . The binding of c-Cbl to VEGFR-2 occurs directly via phosphoTyr1052 and phospho-Tyr1057 of VEGFR-2, as well as indirectly through PLCg1. Phospho-Tyr1057 along with phospho-Tyr1052 on VEGFR-2 recognizes the tyrosine kinase binding domain of c-Cbl (Singh et al., 2007) . Although c-Cbl is recruited to and phosphorylated by VEGFR-2, it is dispensable for ubiquitination and degradation by VEGFR-2 (Singh et al., 2005 (Singh et al., , 2007 . The C-terminus of c-Cbl on the other hand, binds to SH3 domain of PLCg1 and mediates its ubiquitination (Graham et al., 1998 (Graham et al., , 2003 Singh et al., 2007) .
Activation of PLCg1 in endothelial cells is identified as a key downstream mediator of the angiogenic signaling of VEGFR-2. Targeted deletion of PLCg1 in mouse and zebrafish causes in early embryonic lethality due to impairment of vasculogenesis and erythrogenesis (Ji et al., 1997; Liao et al., 2002; Lawson et al., 2003) . Furthermore, mutation of Y1173 on VEGFR-2, a major PLCg1 binding site on VEGFR-2 impairs the ability of VEGFR-2 to stimulate angiogenesis in vitro (Takahashi et al., 2001; Meyer et al., 2003; Rahimi, 2006) . Consistent with the in vitro culture system, the mice homozygous for the mutant VEGFR-2 Y1173F knock-in allele dies with severe defect in vasculogenesis (Sakurai et al., 2005) , further supporting the hypothesis that PLCg1 activation plays a central role in angiogenesis.
To date, the in vivo function of c-Cbl in angiogenesis, in particular in relation to PLCg1 has not been fully established. In this study we aimed to determine the functional consequences of c-Cbl in angiogenesis and its role in PLCg1 activation. Our present data demonstrate that genetic inactivation of c-Cbl in mice results in an increased in phosphorylation of PLCg1 leading to endothelial cell proliferation and angiogenesis. Taken together, our data identifies c-Cbl as an angiogenic suppressor protein, functioning as an endogenous PLCg1 inhibitor.
Results
Loss of c-Cbl in endothelial cells promotes enhanced cell proliferation and tubulogenesis in vitro In previous study we have shown that interfering with c-Cbl activity in endothelial cells significantly increases VEGF-induced PLCg1 phosphorylation and with it sprouting of endothelial cells in vitro (Singh et al., 2005 (Singh et al., , 2007 . To further investigate the functional importance of c-Cbl in angiogenic signaling of VEGFR-2, we analyzed proliferation of porcine aortic endothelial (PAE) cells where we co-expressed wild-type c-Cbl or inactive mutant form of c-Cbl with VEGFR-2. Overexpression of wild-type c-Cbl significantly inhibited VEGF-mediated cell proliferation. Conversely, inhibition of endogenous c-Cbl activity by overexpressing a dominant negatively acting c-Cbl (70Z-c-Cbl) notably increased proliferation of PAE cells in response to VEGF stimulation (Figure 1a) . The increased proliferation of PAE cells overexpressing c-Cbl-70Z was suppressed by treatment of cells with U-73122, a potent PLCg1 inhibitor (Figure 1c) . Moreover, silencing the expression of c-Cbl in PAE cells, also significantly enhanced VEGF-dependent proliferation (data not shown). Altogether, the data suggest that c-Cbl activity in endothelial cells negatively controls VEGF-dependent cell proliferation.
To further link c-Cbl activity to VEGF-dependent endothelial cell proliferation, dermal microvascular endothelial (MVE) cells were isolated from wild-type and c-Cbl knockout mice and analyzed for their ability to undergo VEGF-dependent cell proliferation and tube formation. Our analysis showed that VEGF-induced cell proliferation in c-Cbl null cells was higher compared with endothelial cells derived from wild-type mice (Figure 1e ). To directly demonstrate whether the increased proliferation of endothelial cells derived from c-Cbl null mice is linked to increased PLCg1 activation, we silenced expression of PLCg1 by small interfering RNA and then measured their proliferation in response to VEGF. The PLCg1 small interfering RNA was specifically reduced expression of PLCg1 (Figure 1f ). Silencing the expression of PLCg1 also significantly reduced the VEGF-dependent proliferation of c-Cbl null cells (Figure 1g ). Moreover, treatment of c-Cbl null cells with PLCg1 inhibitor, U-73122, inhibited proliferation in response to VEGF (Figure 1h ), further suggesting that increased proliferation of c-Cbl null cells is linked to elevated activation of PLCg1 in these cells. VEGFdependent activation of PLCg1 is known to regulate tube formation of endothelial cells (Meyer et al., 2003; Husain et al., 2010) . To test the tube formation potential of c-Cbl null cells, we subjected these cells to matrigelbased tube formation assay. The result showed that loss of c-Cbl increases the capillary tube formation of endothelial cells (Figure 1i ). Taken together, the data demonstrate that c-Cbl activity negatively regulates VEGF-dependent angiogenic signaling by targeting PLCg1.
Activation of PLCg1 by growth factors leads to the opening of calcium channels of the endoplasmic reticulum leading to the release of calcium into the cell (Rebecchi and Pentyala, 2000) . To establish whether loss of c-Cbl is associated with PLCg1-dependent intracellular calcium release, we measured intracellular calcium release in endothelial cells derived from c-Cbl null mice versus wild-type cells. Our analysis demonstrates that loss of c-Cbl in endothelial cells results in elevated VEGF-dependent intracellular calcium release compared with the wild-type endothelial cells (Figure 2 ). Taken together, the data suggest that c-Cbl exerts its effect through PLCg1 to inhibit VEGF-dependent angiogenic events in endothelial.
Loss of c-Cbl promotes tumor growth and choroidal neovascularization Angiogenesis is considered the hallmark of tumor growth and metastasis in vivo (Folkman, 1990) . We hypothesized that loss of c-Cbl might augment tumor growth by increasing angiogenesis. To test this hypothesis we measured the growth of murine B16F melanoma cells (B16F cells are originated from C57B1/6 mice and thus are immunologically compatible with the C57BL/6 mice where the c-Cbl null mice was generated) in c-Cbl knockout versus wild-type mice. The result showed that the growth of B16F melanoma cells was significantly higher than the control, wild-type mice (Figures 3a and b) . Indeed, the overgrowth of tumor cells in c-Cbl knockout mice was also extensively accompanied with induction of angiogenesis as was apparent with the formation of large mother blood vessels (Figure 3b ). To further establish the biological importance of c-Cbl in VEGF-mediated angiogenesis, we compared the VEGF-induced angiogenic responses in c-Cbl knockout versus the wild-type mice using in vivo matrigel plug angiogenesis assay. Our data showed that like tumor-induced angiogenesis, VEGF-induced angiogenesis was also elevated in c-Cbl knockout mice compared with wild-type mice ( Figure 3d ). Moreover, protein sample derived from the same tissue showed that phosphorylation of PLCg1 was significantly increased in c-Cbl knockout mice where VEGF was injected (Figures 3d and e) .
Choroidal neovascularization (CNV)/retinal angiogenesis is considered the major pathological characteristic of age-related macular degeneration and VEGF system is identified as a paramount player of its formation. To investigate role of c-Cbl in CNV . PAE cells expressing c-Cbl-70Z were subjected to proliferation assay with the increasing concentration of PLCg1 inhibitor, U73122 (c). Cell lysates derived from the identical cells were subjected for western blot analysis using anti-PLCg1 antibody (d). Serum-starved c-Cbl null MVE cells and wild-type MVE cells at density of 2 Â 10 4 cells per well were stimulated with recombinant human VEGF-A at different concentrations as indicated in the figure legend, and after 48 h they were washed with PBS, harvested by mild trypsinization, and counted with a hematocytometer. Experiments were performed in quadruplicate and three separate experiments were performed and values were presented as means of ±s.d. *Po0.01 versus c-Cbl þ / þ cells (e). c-Cbl null MVE cells were either transfected with control siRNA or PLCg1 and after 48 h expression of PLCg1 was evaluated (f). Expression of PKD (protein kinase D) was analyzed as a loading control. c-Cbl null MVE cells were either transfected with control siRNA or PLCg1 siRNA were subjected to proliferation assay as described above (g). c-Cbl null cells were subjected to proliferation assay as above but cells were also treated with increasing concentration of U73122 (h). c-Cbl null cells and wild-type MVE cells were prepared for tube formation/in vitro angiogenesis as described in materials and method section. Cells were either unstimulated (-) or stimulated with VEGF (100 ng/ml) and pictures were taken after 16 h (i).
n Statistically significant at Po0.05, by ANOVA. A full colour version of this figure is available at the Oncogene journal online. Role of c-Cbl in angiogenesis RD Meyer et al formation, we subjected c-Cbl knockout and wild-type mice to laser-induced CNV formation. CNV was created using the laser photocoagulation method (Funakoshi et al., 2006) . Lesions were induced and followed up to 4 weeks. Fundus photography and angiography was done to document size and leakage from the CNV in these lesions at each visit as describe in the materials and methods section. The follow-up fluorescein angiography of the lesions showed that there were lesions that were progressively larger in size at the 4-week as compared with the earlier time points in the c-Cbl knockout mice ( Figure 4a ). Our analysis showed that leaking CNV was found in 10/14 (71%) lesions in the c-Cbl knockout mice as compared with 6/18 lesions (33%) in the wild-type mice (Figure 4b) . Furthermore, the confluences of lesions were significantly higher in c-Cbl knockout mice compared with the wild-type mice. Indeed, the confluence was found in 6/14 (42%) lesions in c-Cbl knockout and 2/18 (11%) lesions in wild-type mice. Altogether, the data strongly suggest that c-Cbl functions as a negative regulator of tumor-induced angiogenesis and CNV.
Tyrosine phosphorylation of PLCg1 is elevated in c-Cbl-deficient microvascular endothelial cells Activation of VEGFR-2 in PAE cells stimulates phosphorylation of c-Cbl at Y774 (Singh et al., 2007) . To delineate activation of c-Cbl by VEGFR-2 in the context of primary endothelial cells, we initially analyzed phosphorylation of c-Cbl at Y700, Y731 and Y774 in response to VEGF stimulation in primary dermal MVE cells. The data demonstrate that VEGF stimulates c-Cbl tyrosine phosphorylation at Y700, a site involved in the recruitment of VAV, GEF specific for Rho-family GTPases (Miura-Shimura et al., 2003) and Y774, a site along with Y700, involved in the Crk binding to c-Cbl (Feshchenko et al., 1998) (Figures 5a  and c) . Interestingly, Y731, a site involved in the recruitment of PI3-kinase to c-Cbl (Miyazaki et al., 2004; Teckchandani et al., 2005) is not phosphorylated in these primary endothelial cells in response to VEGF stimulation (Figure 5b ). This suggests that Y700 and Y774 on c-Cbl but not Y731 are engaged in c-Cbldependent biological functions in endothelial cells.
Our previous study has identified PLCg1 as a substrate for c-Cbl (Singh et al., 2007) . To analyze the . VEGF mixed with matrigel and injected subcutaneously into c-Cbl-/-and c-Cbl þ / þ mice and pictures was taken after 6 days (c). The tissue from panel c was removed, homogenized and equal amount of proteins were loaded and subjected to western blot analysis using anti-pY783-PLCg1 antibody (d). The same membrane was re-probed with anti-PLCg1 (e). Western blot analysis of phosphorylation of PLCg1 from of cell lysates derived from three mice that were subjected to VEGF-induced angiogenesis was quantified and presented (f).
Role of c-Cbl in angiogenesis RD Meyer et al biological significance of c-Cbl in endothelial cells, dermal MVE cells derived from wild-type and c-Cbl knockout mice were subjected to various biochemical assays in the context of PLCg1 ubiquitination and degradation. To test the effect of loss of c-Cbl in the activation of PLCg1, we analyzed phosphorylation status of PLCg1. Consistent with previous observation (Singh et al., 2007) , loss of c-Cbl significantly increased VEGF-dependent phosphorylation of PLCg1 (Figure 5i) . Loss of c-Cbl had no effect on the phosphorylation of VEGFR-2 or its protein levels (Figures 5h and i) .
PLCg1 is ubiquitinated by c-Cbl in endothelial cells
To examine the biochemical consequence of loss of c-Cbl on PLCg1 in endothelial cells further, we measured ubiquitination of PLCg1 in c-Cbl null endothelial cells. The data show that PLCg1 is ubiquitinated in the wild-type endothelial cells but not in the c-Cbl null cells. Indeed, it seems that PLCg1un-dergoes both poly and monoubiquitination based on its migration pattern as detected by anti-ubiquitin FK2 antibody, which is known to recognize both polyubiquitination and monoubiquitination (Figure 6a ). To further establish ubiquitination of PLCg1, we overexpressed HA-tagged ubiquitin construct in HEK-293 cells ectopically expressing VEGFR-2 and analyzed ubiquitination of PLCg1 where we immunoprecipitated PLCg1 and immunoblotted with anti-HA antibody. The result shows that PLCg1 is ubiquitinated as detected by anti-HA antibody (Figure 6c ). Interestingly, PLCg1 was detected mainly in monoubiquitinated form where it seems that only a small fraction of PLCg1 was polyubiquitinated (Figure 6c) . Altogether, the data demonstrate that PLCg1 is ubiquinated in c-Cbldependent manner.
As in the absence of c-Cbl, PLCg1 is not ubiquitinated, we decided to analyze its degradation rate in response to VEGF stimulation. The result showed that although its ubiquitination requires c-Cbl, degradation of PLCg1 is not regulated by c-Cbl (Figure 6e ). Indeed, PLCg1 seems to be a long-lived and stable protein and stimulation of cells with VEGF up to 60 min had no apparent effect on its degradation (Figures 6e and f) . As shown, VEGF stimulation of wild-type and c-Cbl null cells induced time-dependent downregulation of VEGFR-2 (Figure 6g ), suggesting that c-Cbl activity is not required for downregulation of VEGFR-2 as previously reported (Singh et al., 2005) . Taken together, these results demonstrate that PLCg1 undergoes c-Cbldependent monoubiquitination and ubiquitination attenuates its tyrosine phosphorylation without apparent effect on its degradation.
Discussion
The data presented in this manuscript identify c-Cbl as an important protein, the activity of which critically regulates angiogenesis. Our findings demonstrate that loss of c-Cbl in mouse is associated with increased VEGF, tumor and laser-induced angiogenesis. Endothelial cells derived from c-Cbl null mice were also more sensitive to VEGF-stimulated cell proliferation and their growth was elevated compared with endothelial cells derived from the wild-type mice, and silencing the expression of PLCg1 or treatment of cells with PLCg1 inhibitor reversed this effect. The data further indicate that elevated proliferation of endothelial cells in c-Cbl null cells is likely linked to the state of activation of PLCg1. In support of this possibility tyrosine phosphorylation of PLCg1 and its direct downstream cellular effector, intracellular calcium release was elevated in c-Cbl null cells. Taken together, the data presented in this manuscript strongly implicate c-Cbl as a negative regulator of angiogenesis. The observed effect of c-Cbl on PLCg1 is consistent with the conventional and wellrecognized function of c-Cbl as a negative regulator of receptor tyrosine kinases signaling (Thien and Langdon, 2005) . However, unlike the c-Cbl-mediated degradation of RTKs, c-Cbl mediates ubiquitination of PLCg1 but spares it from degradation.
What is the biological significance of c-Cbl in endothelial cells function and angiogenesis? The earlier studies have demonstrated that loss of c-Cbl alone is dispensable for normal embryonic development (Murphy et al., 1998) where loss of both c-Cbl and Cbl-b was embryonic lethal before E10.5 (Naramura et al., 2002) . Hence, it is reasonable to speculate that c-Cbl activity is not stringently required during Figure 4 Enhanced CNV in c-Cbl null mice: CNV was induced using the laser photocoagulation as described in materials and method section. Both eyes of each mouse were treated and four spots were placed in the peripapillary area about 1-2 disc diameter from the optic nerve. Angiograms were performed every week after the laser induction. The angiograms from week 2 to 4 are shown (a). The confluence of CNV in c-Cbl null mice versus wild-type mice is shown. In the c-Cbl null mice CNV was found to be confluent in 6 of the 14 (42%) lesions, as compared with 2 lesions becoming confluent out of the 18 (11%) lesions in the wild-type mice (b).
development, and the function of Cbl family proteins may be compensatory in their ability to regulate the activity of target proteins. It has also well recognized that in pathological angiogenesis such as tumor-induced angiogenesis, whereas tumors are known to cooperate normal physiological pathways to induce angiogenesis, tumor-associated vessels, however, are leaky, torturous and defective in their interaction with smooth muscle cells and pericytes (Folkman, 1990; Adams and Alitalo, 2007) . Recent anti-VEGF studies also revealed that these agents increase normalization of endothelial cells (Fukumura and Jain, 2007) . Consistent with distinct phenotype of pathological angiogenesis there is a growing number of mouse models in which tumormediated angiogenesis is defective, whereas embryonic angiogenesis is not (Woodman et al., 2003; Zeng et al., 2006; Zhang et al., 2008) , suggesting that perhaps c-Cbl selectively plays a role in pathological angiogenesis.
The c-Cbl protein is tyrosine phosphorylated at multiple sites including, Y700, Y774 and Y731 in response to growth factor stimulation (Thien and Langdon, 2005) . Our analysis shows that VEGF stimulation of endothelial cells selectively induces phosphorylation of c-Cbl at Y700 and Y774 but not Y731. Phosphorylation of c-Cbl at Y731 is linked to recruitment of PI3-kinase to c-Cbl, where in certain systems is suggested to provide growth stimulatory signal (Fang and Liu, 2001) . Differential tyrosine phosphorylation of c-Cbl by VEGFR-2 or VEGFR-2 activated tyrosine kinases suggests that c-Cbl activity is uniquely regulated by this receptor system and it may have a distinct role in the integration of angiogenic signaling of VEGFR-2.
Conjugation of ubiquitin to target proteins is recognized to regulate a broad range of cellular functions beyond protein degradation including, kinase activation, endocytosis and protein trafficking (Ravid and Hochstrasser, 2008; Hochstrasser, 2009; Schwartz and Ciechanover, 2009) . Despite the clear importance of ubiquitination in protein degradation in other systems, ubiquitination of PLCg1 has no significant role in its degradation. Another interesting aspect of our finding is that PLCg1 is mainly monoubiquitinated. This may explain why PLCg1 is spared from degradation. Figure 5 Loss of c-Cbl in endothelial cells increases tyrosine phosphorylation of PLCg1 but has no effect on its proteolysis. Serum-starved primary MVE cells either unstimulated (À) or stimulated with VEGF-A for 10 min and cells lysed and whole-cell lysates were blotted for phospho-Y700-Cbl (a), phospho-Y731-Cbl (b), phospho-Y774-Cbl (c) and total c-Cbl (d). Serum-starved c-Cbl þ / þ and c-CblÀ/À MVE cells were either unstimulated (À) or stimulated with VEGF for 10 min, and whole-cell lysates were blotted with anti-phospho-Y783 PLCg1 (e), anti-PLCg1 (g), anti-phospho-Y1173-VEGFR-2 (h), anti-VEGFR-2 (i) and anti-c-Cbl (j) antibodies. Quantification of phosphorylation of PLCg1 from panel i in c-Cbl þ / þ and c-CblÀ/À MVE cells is shown (f). A full colour version of this figure is available at the Oncogene journal online.
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Monoubiquitination is mainly linked to endocytosis where polyubiquitination is suggested to target proteins for proteasome-mediated degradation (Ravid and Hochstrasser, 2008) . Instead of degradation, ubiquitination of PLCg1 suppresses its tyrosine phosphorylation. Although from the current data presented in this manuscript it is not clear how ubiquitination achieves suppression of tyrosine phosphorylation of PLCg1, however, conjugating a single ubiquitin onto one or more lysines on PLCg1, could influence dephosphorylation of Y783 by protein tyrosine phosphatases. Moreover, conjugation of ubiquitin to PLCg1 could alter its association with other proteins, though its ubiquitination does not alter its binding to VEGFR-2 (Singh et al., 2007) .
In summary, our observation suggests that c-Cbl activity is required for angiogenesis by functioning as a molecular switch to fine-tune angiogenic events during pathological conditions such as cancer and other angiogenesis-associated diseases. This study provides a better understanding of the molecular mechanism of pathological angiogenesis and key role of c-Cbl signaling in these events. Our study further suggests that c-Cbl may be a novel target for the treatment for angiogenesisassociated diseases.
Materials and methods
Cell culture and cell lines Primary mouse dermal MVE cells were grown in HUVEC medium plus growth factor supplements and penicillin/ streptomycin (Enzo, Inc, Plymouth Meeting, PA, USA). HEK-293 and PAE cells were grown in 10% fetal bovine serum. PAE cells lack endogenous expression of VEGFR-2, expression of VEGFR-2 in these cells was established by retroviral system (Rahimi et al., 2000) . Plasmids, growth factors and antibodies c-Cbl and 70Z-Cbl constructs were described previously (Singh et al., 2007) . Chimeric VEGFR-2 (CKR) and its expression in PAE cells is described previously (Rahimi et al., 2000) . AntiPLCg1 antibody and anti-phospho-783-PLCg1 were purchased from Biosource/Invirogene (Carlsbad, CA, USA), Anti-Ubiquitin (FK2) antibody was from Biomol (Plymouth Meeting, PA, USA), anti-CD31 antibody was from Abcam (Cambridge, MA, USA) VEGF-A was purchased from R&D (Minneapolis, MN, USA).
Immunoprecipitation and western blot analysis Equal numbers of cells from the indicated cells were grown until 80-90% confluent. After serum starvation, cells were left either resting or stimulated with VEGF-A at 371C as indicated in the figure legends. Cells were prepared and lysed and subjected to western blot analysis as described (Singh et al., 2007; Meyer et al., 2008) . In some occasions western blot analyzes were quantified using NIH image J software (http:// rsbweb.nih.gov/ij/index.html).
Isolation of dermal microvascular endothelial cells
Mouse dermal MVE cells were isolated from the skin of 4-weeks-old mice and further purified consecutively by anti-CD31, a maker for endothelial marker and hematopoietic cells and anti-CD146 (Millipore/Chemicon, Billerica, MA, USA), a marker for endothelial cells using MACS LS separation column (Miltenyi Biotec Inc., Auburn, CA, USA).
Endothelial cell tube formation assay
Endothelial cells were seeded on matrigel with endothelial cell growth medium (Clonetics Co., San Diego, CA, USA) in the absence or presence of VEGF and photographed after 16 h. Experiments were repeated three times.
Cell proliferation assay
Cell proliferation of Primary endothelial cells was evaluated by direct cell counting as described (Rahimi et al., 2009) . Briefly, endothelial cells were seeded at a density of 2 Â 10 4 cells per well in 24-well plates and cultured overnight; the cells were then incubated in serum-free medium for 12 h. Cells were stimulated with recombinant human VEGF-A at different concentrations as indicated in figure legends, and after 48 h they were washed with phosphate-buffered saline, harvested by mild trypsinization, and counted with a hematocytometer. Experiments were performed in quadruplicate and values were presented as means of ± s.d. Proliferation of PAE cells expressing c-Cbl and 70Z-Cbl was measured by 3 H-thymidine incorporation assay as described before (Meyer et al., 2003) . Comparison of the different parameters for the each group was determined by repeated measures analysis of variance (ANOVA). Significant differences were assigned using KruskalWallis post hoc test. The criterion for significance for all the tests was set at p, 0.05. Analysis was done in GraphPad Prism v4.0b (GraphPad Software, San Diego, CA, USA).
Tumor angiogenesis
Mice (four animals for each experiment) were injected with matrigel (10 mg/ml), plus B16 melanoma cells (1 Â 10 7 ) or VEGF-A. Before injection, the animals were sedated with Avertin (0.3 ml per 20 g mouse). Using 25-gauge needle 0.3 ml of matrigel mixture was injected subdermally into mice. After 12 days (or as outlined in the figure legends), animals were euthanized and the tumor-injected tissues were removed for further analysis. In some experiments the growth of B16 melanoma cells were measured over the time of experiment. Tumor size was measured using caliper as described (Woodman et al., 2003) . All the statistical analyzes were done in GraphPadPrism v4.0b (GraphPad Software).
Calcium flux assay
The assay is performed as described (Meyer et al., 2004) . Briefly, cells were grown on 25-mm round glass coverslips and serum-starved for 12-18 h. Cells were incubated in an HEPESbuffered saline solution with 4 mM fluo-3 AM, supplemented with 0.02% pluronic acid for 30 min at 37 1C. The live cells were placed in an open chamber (Molecular Probes, Inc., Eugene, OR, USA) and positioned on the stage of a Zeiss LSM (Thornwood, NY, USA) 510 Axiovert confocal laser scanning microscope equipped with an Argon laser. For each experiment, cells were scanned for at least 5 to 10 s before the addition of VEGF-A to establish a base-line fluorescence reading. All the readings were made while continuously scanning the cells every 789 milliseconds.
Laser-induced choroidal neovascularization (CNV) and fluorescein angiography CNV was induced using the laser photocoagulation method as described (Funakoshi et al., 2006) . Green light at 532 nm, 0.05 sec exposure, 200 mW power and 50-micron spot size was used from a coherent dye laser (Novus Omni Coherent; Lumenis, Santa Clara, CA, USA). Both eyes of each mouse were treated and four spots were placed in the peripapillary area about 1-2 disc diameter from the optic nerve. Those spots that showed hemorrhagic complication were excluded from further evaluation in the follow-up study. A total of 14 lesions were created in the knockout mice and 18 lesions were created in the wild mice. Fluorescein angiography was performed on the TRC 50VT camera and Imagenet system, Topcon, Paramus, NJ, USA. A standard 20 D lens was placed in contact with the fundus camera lens to capture the mouse fundus photographs and angiograms. Intraperitoneal injection of 0.2 ml of 1% sodium fluorescein (Akorn, Decatur, IL, USA) was in the mouse. Angiograms were done at 1, 2, 3 and 4 weeks after the laser induction. Two masked retina specialists graded all the angiograms. The angiograms were graded based on previously described grading scheme: 0 (no leakage), 1 (questionable leakage), 2A (hyperfluorescence increasing in intensity but not in size) 2B (hyperfluorescence increasing in intensity and size).
